search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
MEDICAL DEVICES


ivain  am i tals throgh the firms devices, the trials they are being sed in and how they collect data otside the black box. Image credit: VivaLink


sensor itself. When the device is back in range with a mobile device or gateway that can then transmit data to the cloud, it automatically synchronises it. That’s so important for collecting continuous real-world data in your typical remote environment.


KP: How do you support your clients with data analysis?


SL: In addition to providing data – both the raw and the processed or smoothed-out data – we also provide advanced algorithms. We have algorithms that can detect over 15 different arrhythmia types, for example. Not every clinical research provider will have their own software to process the data, so we provide that as part of our service. We’re looking at other types of more advanced algorithms and software to process data, so that it presents not just data, but more of a clinical insight into a certain disease state.


KP: What are some of the trials in which your devices are being used? SL: We have a trial ongoing at the University


50 | Outsourcing In Clinical Trials


of California, San Francisco, which is very interesting as it’s one of the largest of its type using a continuous ECG monitor like ours in a population of 3,000 participants. The purpose of the trial is to basically identify biomarkers that give you early warning signs of atrial fibrillation Aib, which is the most common arrhythmia problem and causes a lot of issues, including increased levels of strokes. The way it’s treated today is more symptom-based. This study is to see if we can get an earlier indication of the onset of Aib to try to condct some kind of preventive medicine. To conduct such a large study like this, we need a lot of ECG data – something that can continuously capture the patient’s data in real- world situations over a long period of time. It’s an up to 10-year study that is now in its third year. The protocol calls for patients to wear our patch for about a week at a time, every month, on an ongoing basis. The unique design of our technology is very


well suited for that and so are the qualitative features. Our sensors are very small, non- intrusive and comfortable. You can wear one and you won’t even notice it under your


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72